Juliana (Jules) Haggerty is leading a new UK Centre of Excellence to enable radical innovation in the field of Intracellular Drug Delivery for nucleic acid therapies and vaccines, working with partners across the UK’s academic and research ecosystem. She has worked at CPI since 2014, supporting their RNA vaccine programmes for the UK Vaccine Taskforce in 2020 and providing expert advice and due diligence on legacy activities and onshoring throughout 2021. Jules sits on the Technology and Innovation committee of the UK Medicines Manufacturing Industry Partnership and has significant expertise in the use of public/ private funding and collaborative R&D models to advance technology and innovation. Jules has a BSc (Hons) degree in Physiological Sciences and an EngDoc in Biopharmaceutical Process Development from Newcastle University. In her early career, she spent 8 years at global Life Sciences company, Millipore, working on advanced technology development and best practice for biopharmaceutical manufacture and further developed expertise in image analysis, machine learning and algorithm development during her doctoral studies.